Bioxyne (ASX: BXN) has secured a significant $50 million exclusive German supply agreement with ADREXpharma, marking a substantial expansion into Europe's largest medicinal cannabis market.
The deal, which includes a $25 million minimum commitment in the first year, bolsters near-term revenue visibility and extends the company's international reach.
The contract, signed by Bioxyne subsidiary Breathe Life Sciences, also features an automatic 12-month renewal for the agreement.
This latest agreement expands on an initial supply agreement executed with ADREX in June 2025. It reflects increasing demand for Breathe Life Sciences' GMP-certified products across Europe.
European Market Expansion
Germany is Europe's largest medicinal cannabis market, estimated at 200 tonnes per annum.
This agreement positions Bioxyne prominently within this significant growth territory.
This deal supports Bioxyne's strategic entry and deeper penetration into a key European market.
The supply will include GMP-manufactured Australian cannabis flower and other products.
Bioxyne's broader European strategy includes previous international expansion efforts into the UK and other regions.
Revenue Visibility and Production Impact
The $25 million minimum commitment in the first 12 months provides Bioxyne with enhanced near-term revenue visibility.
This reduces demand uncertainty compared to discretionary orders.
The agreement creates a defined demand pathway for Bioxyne's GMP-manufactured medicinal cannabis products directly into Germany.
This arrangement supports outbound volume execution and strengthens Bioxyne’s commercial positioning in a major European market.
Context: Other Recent International Deals
Bioxyne has been active in expanding its global footprint. The company recently expanded its LATAM presence with a supply agreement for Dr Watson medicinal cannabis flower into Costa Rica.
The initial shipment for this deal is expected to exceed $500,000.
The company also has a manufacturing agreement with Aurora Cannabis that initially involved medicinal cannabis oil deliveries into Australia, but is now expanding to include GMP-manufactured vapes for distribution in Australia, the UK, and Germany.
Bioxyne previously reported strong financial results for H1 FY2026 including record revenue of AUD31.3 million and an upgraded FY26 EBITDA guidance to AUD16.5 million to AUD19 million.
These results were driven by capacity expansion and new international contracts.
Outlook and Risks
Bioxyne’s new German supply agreement with ADREXpharma represents a significant step in its European expansion.
It provides substantial revenue visibility and market access.
However, investors should remain aware of execution risks in meeting GMP supply schedules and sustaining German market demand over the 24-month term.
The company also faces ongoing challenges related to regulatory approvals across its international ventures, along with potential timing and funding considerations for future growth initiatives.
